First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with…
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall…